High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*-Reference-Cited by-同舟云学术

High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma*

Published:2021-08-18 Issue:6 Volume:185 Page:1186-1199
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Westphal D.¹²^ORCID,Garzarolli M.¹,Sergon M.³^ORCID,Horak P.⁴⁵^ORCID,Hutter B.⁴⁶⁷^ORCID,Becker J.C.⁸⁹,Wiegel M.¹,Maczey E.¹⁰,Blum S.¹¹^ORCID,Grosche‐Schlee S.¹²,Rütten A.¹³,Ugurel S.⁸^ORCID,Stenzinger A.⁴¹⁴^ORCID,Glimm H.¹⁵¹⁶¹⁷¹⁸^ORCID,Aust D.²³¹⁹^ORCID,Baretton G.²³¹⁹^ORCID,Beissert S.¹²^ORCID,Fröhling S.⁴⁵^ORCID,Redler S.²⁰^ORCID,Surowy H.²⁰^ORCID,Meier F.¹²²¹^ORCID

Affiliation:

1. Department of Dermatology University Hospital Carl Gustav Carus at Technische Universität (TU) Dresden Dresden Germany

2. National Center for Tumor Diseases (NCT), Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany; and Helmholtz‐Zentrum Dresden‐Rossendorf (HZDR) Dresden Germany

3. Institute of Pathology University Hospital Carl Gustav Carus at TU Dresden Dresden Germany

4. German Cancer Consortium (DKTK) Heidelberg Germany

5. Division of Translational Medical Oncology National Center for Tumor Diseases (NCT) Heidelberg and DKFZ Heidelberg Germany

6. Computational Oncology Molecular Diagnostics Program NCT Heidelberg and DKFZ Heidelberg Germany

7. Division of Applied Bioinformatics DKFZ Heidelberg Germany

8. Department of Dermatology University Hospital Essen Essen Germany

9. Translational Skin Cancer Research DKTK Partner Site Essen Essen Germany

10. Department of Dermatology University Medical Center Tübingen Tübingen Germany

11. Institute and Policlinic of Diagnostic and Interventional Radiology University Hospital Carl Gustav Carus at TU Dresden Dresden Germany

12. Clinic and Policlinic of Nuclear Medicine University Hospital Carl Gustav Carus at TU Dresden Dresden Germany

13. Dermatopathology Friedrichshafen Friedrichshafen Germany

14. Institute of Pathology University Hospital Heidelberg Heidelberg Germany

15. Translational Functional Cancer Genomics NCT Heidelberg and DKFZ Heidelberg Germany

16. Department of Translational Medical Oncology NCT Dresden and DKFZ Dresden Germany

17. Center for Personalized Oncology University Hospital Carl Gustav Carus at TU Dresden Dresden Germany

18. DKTK Dresden Germany

19. Tumor and Normal Tissue Bank of the UCC/NCT Site Dresden NCT Dresden and University Hospital Carl Gustav Carus at TU Dresden Dresden Germany

20. Institute of Human Genetics Medical Faculty and University Hospital Düsseldorf Heinrich Heine University Düsseldorf Düsseldorf Germany

21. Skin Cancer Center at the University Cancer Center Dresden University Hospital Carl Gustav Carus at TU Dresden Dresden Germany

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.20604

Reference59 articles.

1. Oncogenic Differentiation of the Intraepidermal Eccrine Sweat Duct: Eccrine Poroma, Poroepithelioma and Porocarcinoma

2. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature

3. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma

4. Eccrine porocarcinoma

5. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases;Journal of Investigative Dermatology;2023-07

2. Eccrine Porocarcinoma: A Review of the Literature;Diagnostics;2023-04-16

3. Diagnosis and Management of Porocarcinoma;Cancers;2022-10-25

4. Analysis on internal mechanism of zedoary turmeric in treatment of liver cancer based on pharmacodynamic substances and pharmacodynamic groups;Chinese Herbal Medicines;2022-10

5. Current Treatment Options for Cutaneous Adnexal Malignancies;Current Treatment Options in Oncology;2022-03-26